Inventor · disambiguated record
Flemming S. Nielsen
Also filed as: NIELSEN FLEMMING S · NIELSEN FLEMMING SEIER
9 granted patents·9 pending applications·153 citations·filing 2011–2025
90Inventor score
Top patents by PatentIndex Score
18 records- 0197US11382957B2Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acidNOVO NORDISK AS·Filed 2021·Granted Jul 12, 2022·11 cites·9 claims
- 0297US10960052B2Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acidNOVO NORDISK AS·Filed 2018·Granted Mar 30, 2021·19 cites·18 claims
- 0396US10278923B2Oral dosing of GLP-1 compoundsNOVO NORDISK AS·Filed 2017·Granted May 7, 2019·29 cites·23 claims
- 0495US10086047B2Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acidNOVO NORDISK AS·Filed 2016·Granted Oct 2, 2018·26 cites·10 claims
- 0593US9278123B2Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acidSAUERBERG PER·Filed 2011·Granted Mar 8, 2016·40 cites·19 claims
- 0691US11033499B2Tablet formulation comprising a GLP-1 peptide and a delivery agentNOVO NORDISK AS·Filed 2018·Granted Jun 15, 2021·8 cites·16 claims
- 0789US9993430B2Tablet formulation comprising semaglutide and a delivery agentNOVO NORDISK AS·Filed 2013·Granted Jun 12, 2018·18 cites·10 claims
- 0888US2024277817A1Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acidNOVO NORDISK AS·Filed 2024·Application pending·0 cites
- 0984US2023302092A1Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acidNOVO NORDISK AS·Filed 2023·Application pending·0 cites
- 1081US12239739B2Oral dosing of GLP-1 compoundsNOVO NORDISK AS·Filed 2019·Granted Mar 4, 2025·2 cites·27 claims
- 1181US2022313786A1Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acidNOVO NORDISK AS·Filed 2022·Application pending·0 cites
- 1274US2025213485A1Oral Dosing of GLP-1 CompoundsNOVO NORDISK AS·Filed 2025·Application pending·0 cites
- 1370US2016067184A1Oral Dosing of GLP-1 CompoundsNOVO NORDISK AS·Filed 2014·Application pending·0 cites
- 1466US2021275458A1Tablet formulation comprising a glp-1 peptide and a delivery agentNOVO NORDISK AS·Filed 2021·Application pending·0 cites
- 1563US2022062184A1Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release CoatingNOVO NORDISK AS·Filed 2021·Application pending·0 cites
- 1645US2015141336A1Pancreatic Peptide Compounds and UseNOVO NORDISK AS·Filed 2013·Application pending·0 cites
- 1741US2018263915A1Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release CoatingNOVO NORDISK AS·Filed 2016·Application pending·0 cites
- 1836US10265384B2Tablets comprising GLP-1 agonist and enteric coatingNOVO NORDISK AS·Filed 2016·Granted Apr 23, 2019·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when Flemming S. Nielsen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →